Cited by 215Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

Sex and ApoE Genotype Differences in Treatment Response to Two Doses of Intranasal Insulin in Adults with Mild Cognitive Impairment or Alzheimer's Disease

Open access
Claxton, Amy, Baker, Laura D., Wilkinson, Charles W., Trittschuh, Emily H., Chapman, Darla, Watson, G. Stennis, Cholerton, Brenna, Plymate, Stephen R. +2 more·2013·Journal of Alzheimer’s Disease

Abstract

A previous clinical trial demonstrated that four months of treatment with intranasal insulin improves cognition and function for patients with Alzheimer's disease (AD) or mild cognitive impairment (MCI), but prior studies suggest that response to insulin treatment may differ by sex and ApoE ε4 carriage. Thus, responder analyses using repeated measures analysis of covariance were completed on the trial's 104 participants with MCI or AD who received either placebo or 20 or 40 IU of insulin for 4 months, administered by a nasal delivery device. Results indicate that men and women with memory impairment responded differently to intranasal insulin treatment. On delayed story memory, men and women showed cognitive improvement when taking 20 IU of intranasal insulin, but only men showed cognitive improvement for the 40 IU dose. The sex difference was most apparent for ApoE ε4 negative individuals. For the 40 IU dose, ApoE ε4 negative men improved while ApoE ε4 negative women worsened. Their ApoE ε4 positive counterparts remained cognitively stable. This sex effect was not detected in functional measures. However, functional abilities were relatively preserved for women on either dose of intranasal insulin compared with men. Unlike previous studies with young adults, neither men nor women taking intranasal insulin exhibited a significant change in weight over 4 months of treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-122308

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Craft and colleagues found that short-term intranasal insulin improved cognition and lowered neurotoxic Aβ42 in early AD patients.

    “Craft and co-workers investigated insulin resistance in AD7,38 and reported improved cognition in early AD patients and decreased levels of neurotoxic Aβ42 following a short-term treatment with intranasal insulin98.”

    From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [98]

    The Introduction (page unavailable) reports improved memory and cognitive scores after intranasal insulin in people with early AD or MCI. It says amyloid-β levels may be modulated, but neither the Introduction nor the retrieved passages report a decrease in Aβ42; that part of the claim is unsupported. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • The results of intranasal insulin differed according to gender and apoE genotype.

    “The results differed according to gender and apoE genotype98.”
  • Studies in larger samples of male and female participants with cognitive impairments only yielded sporadic indicators of a sex difference in response to IN insulin.

    “studies in larger samples of male and female participants with cognitive impairments only yielded sporadic indicators of a sex difference in the response to IN insulin, 74”

    From Intranasal insulin (2021) · cites this paper as [74]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Claxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., Cholerton, B., Plymate, S. R., Arbuckle, M., & Craft, S.
Affiliations
  • University of Washington (US)
  • Wake Forest University Health Sciences (US)
  • VA Puget Sound Health Care System (US)
Corresponding author
Craft, Suzanne
Venue
Journal of Alzheimer’s Disease
Published
2013-05-21
Volume
35
Issue
4
Pages
789-797
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W1553529648
Cited by
215
References
44
Citations by year
2026: 4 · 2025: 11 · 2024: 15 · 2023: 18 · 2022: 23 · 2021: 23 · 2020: 23 · 2019: 27 · 2018: 14 · 2017: 20 · 2016: 14 · 2015: 12 · 2014: 6 · 2013: 5
FWCI
8.56
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • National Institute on Aging (AG027415, T32AG000258, R01AG027415)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
Keywords
intranasal insulin, Alzheimer's disease
MeSH terms
Administration, Intranasal, Aged, Alzheimer Disease, Body Weight, Female, Genotype, Humans, Hypoglycemic Agents, Insulin, Male, Neuropsychological Tests, Sex Characteristics, Body Mass Index, Treatment Outcome, Apolipoprotein E4, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review